265 related articles for article (PubMed ID: 11458057)
1. Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate.
Spetz AC; Hammar M; Lindberg B; Spångberg A; Varenhorst E;
J Urol; 2001 Aug; 166(2):517-20. PubMed ID: 11458057
[TBL] [Abstract][Full Text] [Related]
2. Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study.
Hedlund PO; Henriksson P
Urology; 2000 Mar; 55(3):328-33. PubMed ID: 10699602
[TBL] [Abstract][Full Text] [Related]
3. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.
Hedlund PO; Ala-Opas M; Brekkan E; Damber JE; Damber L; Hagerman I; Haukaas S; Henriksson P; Iversen P; Pousette A; Rasmussen F; Salo J; Vaage S; Varenhorst E;
Scand J Urol Nephrol; 2002; 36(6):405-13. PubMed ID: 12623503
[TBL] [Abstract][Full Text] [Related]
4. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
[TBL] [Abstract][Full Text] [Related]
5. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.
Hedlund PO; Damber JE; Hagerman I; Haukaas S; Henriksson P; Iversen P; Johansson R; Klarskov P; Lundbeck F; Rasmussen F; Varenhorst E; Viitanen J;
Scand J Urol Nephrol; 2008; 42(3):220-9. PubMed ID: 18432528
[TBL] [Abstract][Full Text] [Related]
6. Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer.
Quella SK; Loprinzi CL; Sloan J; Novotny P; Perez EA; Burch PA; Antolak SJ; Pisansky TM
J Urol; 1999 Jul; 162(1):98-102. PubMed ID: 10379749
[TBL] [Abstract][Full Text] [Related]
7. Relationship between hot flashes and distress in men receiving androgen deprivation therapy for prostate cancer.
Ulloa EW; Salup R; Patterson SG; Jacobsen PB
Psychooncology; 2009 Jun; 18(6):598-605. PubMed ID: 18942660
[TBL] [Abstract][Full Text] [Related]
8. Megestrol acetate for the treatment of hot flashes in men undergoing hormone ablation therapy or orchiectomy.
Lajiness MJ
Urol Nurs; 2007 Dec; 27(6):556-7. PubMed ID: 18217540
[No Abstract] [Full Text] [Related]
9. Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial.
Hedlund PO; Johansson R; Damber JE; Hagerman I; Henriksson P; Iversen P; Klarskov P; Mogensen P; Rasmussen F; Varenhorst E;
Scand J Urol Nephrol; 2011 Nov; 45(5):346-53. PubMed ID: 21627403
[TBL] [Abstract][Full Text] [Related]
10. Parenteral medroxyprogesterone for the management of luteinizing hormone releasing hormone induced hot flashes in men with advanced prostate cancer.
Langenstroer P; Kramer B; Cutting B; Amling C; Poultan T; Lance R; Thrasher JB
J Urol; 2005 Aug; 174(2):642-5. PubMed ID: 16006929
[TBL] [Abstract][Full Text] [Related]
11. The role of parenteral polyestradiol phosphate in the treatment of advanced prostatic cancer on the threshold of the new millennium.
Mikkola A; Ruutu M; Aro J; Rannikko S; Salo J
Ann Chir Gynaecol; 1999; 88(1):18-21. PubMed ID: 10230677
[TBL] [Abstract][Full Text] [Related]
12. Health-related quality of life among patients with metastatic prostate cancer.
Albertsen PC; Aaronson NK; Muller MJ; Keller SD; Ware JE
Urology; 1997 Feb; 49(2):207-16; discussion 216-7. PubMed ID: 9037282
[TBL] [Abstract][Full Text] [Related]
13. Managing hot flashes in men being treated for prostate cancer.
Baum NH; Torti DC
Geriatrics; 2007 Nov; 62(11):18-21. PubMed ID: 17999566
[TBL] [Abstract][Full Text] [Related]
14. Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy.
Nishiyama T; Kanazawa S; Watanabe R; Terunuma M; Takahashi K
Int J Urol; 2004 Sep; 11(9):735-41. PubMed ID: 15379937
[TBL] [Abstract][Full Text] [Related]
15. Incidence and management of hot flashes in prostate cancer.
Spetz AC; Zetterlund EL; Varenhorst E; Hammar M
J Support Oncol; 2003; 1(4):263-6, 269-70, 272-3; discussion 267-8, 271-2. PubMed ID: 15334868
[TBL] [Abstract][Full Text] [Related]
16. [Intramuscular depot estrogens (Estradurin) in treatment of patients with prostate carcinoma. Historical aspects, mechanism of action, results and current clinical status].
Stege R; Carlström K; Hedlund PO; Pousette A; von Schoultz B; Henriksson P
Urologe A; 1995 Sep; 34(5):398-403. PubMed ID: 7483157
[TBL] [Abstract][Full Text] [Related]
17. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma.
Sciarra A; Monti S; Gentile V; Mariotti G; Cardi A; Voria G; Lucera R; Di Silverio F
Prostate; 2003 May; 55(3):168-79. PubMed ID: 12692782
[TBL] [Abstract][Full Text] [Related]
18. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
19. Measuring hot flashes in men treated with hormone ablation therapy: an unmet need.
Kattan MW
Urol Nurs; 2006 Feb; 26(1):13-8. PubMed ID: 16562382
[No Abstract] [Full Text] [Related]
20. Combined androgen blockade in the management of advanced prostate cancer: a sensible or ostensible approach.
Ansari MS; Gupta NP; Hemal AK; Dogra PN; Seth A
Int J Urol; 2004 Dec; 11(12):1092-6. PubMed ID: 15663681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
